



# The influence of obesity and adipose tissue mediators on the course of sarcoidosis


Karol Bączek M.D., Wojciech Piotrowski M.D. PhD  
Department of Pneumology, Medical University of Lodz

## Introduction

- Sarcoidosis is a systemic disease defined by non-caseating granulomas in various organs, with progression mainly dependent on lung manifestations and extrapulmonary features
- Various cytokines such as TNF-alpha, interferon-gamma, and IL-17 play a crucial role in the inflammation process and persistence of sarcoidosis<sup>1</sup>.
- Adipokines (released by adipose cells) play an important role in the pathogenesis of many inflammatory diseases, such as asthma<sup>2</sup>, connective tissue diseases<sup>3</sup>, and tuberculosis<sup>4</sup> by angiogenesis, lipid metabolism, and immune system regulation, which may affect the mechanism of sarcoidosis
- The relationship between obesity and sarcoidosis has yet to be thoroughly investigated. Furthermore, the interactions between the adipokines with vitamin D metabolism and calcium homeostasis—both of which may be disrupted in sarcoidosis—remain unclear.

**The aim of the study is to evaluate the influence of obesity and alterations in body composition and concentrations of selected adipokines on the course of sarcoidosis and calcium metabolism**

## Methods



**The correlation between adipokine concentrations and other parameters with clinical severity criteria and BMI will be evaluated**

### Inclusion criteria

- Diagnosis of sarcoidosis according to ATS criteria
- BMI ≥ 30
- Written consent
- Age 18-80

### Exclusion criteria

- Other chronic respiratory diseases
- Respiratory tract infection within the last 4 weeks
- Use of immunomodulatory drugs (systemic steroid therapy, immunosuppression such as methotrexate, azathioprine, hydrochloroquine, infliximab, adalimumab)
- Chronic diseases that, in the researchers' opinion, could affect the inflammatory parameters being studied (endocrinological diseases, diabetes)

### Outcomes

- Disease progression:
  - new symptoms or exacerbation of symptoms
  - ≥ 10% decline in FVC, ≥ decline in TLCO
  - >50m distance reduction in 6-MWT
  - appearance/worsening of extrapulmonary manifestations
  - initiation of pharmacotherapy
  - treatment intensification
- Remission status

## Results

- Obtained approval from the Bioethics Committee at the Medical University of Lodz, number RNN/249/22/KE
- 15 patients recruited from Study group
- 10 patients recruited from Control group
- **Each patient had the following tests performed:** Chest HRCT, Pulmonary function tests (spirometry, TLCO, 6-MWT), ECG, Blood sampling (total calcium, 25(OH)vitamin D, 1,25(OH)<sub>2</sub>vitamin D, creatinine, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, C-reactive protein - CRP, complete blood count), systemic inflammation markers (IL-6, TNF-alpha), sarcoidosis activity markers (ACE, SIL2R, neopterin, YKL-60), BMI, waist circumference, body composition analysis by electrical bioimpedance, FAS scale, SHQ questionnaire.
- **Each patient had the blood sample secured for adipokines measurement – biobank of the Laboratory of Patobiology of Respiratory System at the Pneumology Department – adiponectin, leptin, resistin, chemerin, wisfatin, progranulin, FSTL-1**

## References

- 1 - Kaiser Y, Eklund A, Grunewald J. Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder. *Eur Respir J* 2019; 54: 1802153 [https://doi.org/10.1183/13993003.021532018].
- 2 - Ziara D, Machura E, Ziara KT, Swietochowska E, Oswiecimska JM, Kasperska-Zajac A. Serum resistin levels are elevated in schoolchildren with atopic asthma. *Neuro Endocrinol Lett.* 2013;34(3):212-6. PMID: 23685419.
- 3 - Żółkiewicz J, Stochmal A, Rudnicka L. The role of adipokines in systemic sclerosis: a missing link? *Arch Dermatol Res.* 2019 May;311(4):251-263. doi: 10.1007/s00403-019-01893-1. Epub 2019 Feb 26. PMID: 30806766.
- 4 - Zheng Y, Ma A, Wang Q, Han X, Cai J, Schouten EG, Kok FJ, Li Y. Relation of leptin, ghrelin and inflammatory cytokines with body mass index in pulmonary tuberculosis patients with and without type 2 diabetes mellitus. *PLoS One.* 2013 Nov 8;8(11):e80122. doi: 10.1371/journal.pone.0080122. PMID: 24260344.